The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing ...

Sheffield Teaching Hospitals NHS Foundation Trust has become the only site in the UK to open a groundbreaking international trial which could revolutionise care for people living with a rare and ...

The partnership reflects the UAE’s growing role as a hub for medical innovation Abu Dhabi, UAE: A landmark collaboration between New York University Abu Dhabi (NYUAD), Yas Clinic – Khalifa City, and ...

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for MS - a set of guidelines to help healthcare professionals provide accurate, timely multiple sclerosis diagnosis — were ...

ABU DHABI - New York University Abu Dhabi (NYUAD), Yas Clinic- Khalifa city, and Abu Dhabi Stem Cells Centre (ADSCC) have announced a pioneering collaboration that brings new, AI-supported MRI ...

Several factors were associated with increased pain among patients with systemic sclerosis, including the pain type, pain location, and disease subtype. Nearly all patients with systemic sclerosis ...

Christina Applegate knows her loved ones are navigating a difficult chapter. But while her teenager hasn’t outwardly expressed the difficulties with seeing her mother ill, the 53-year-old notices a ...

People with multiple sclerosis (MS) may show warning signs long before classic symptoms appear — and mental health concerns could be among the first red flags, according to new research. A University ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from induced pluripotent stem cells (iPSCs) loosened life-limiting skin and ...

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...

Safety and efficacy of chimeric antigen receptor (CAR)–T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients. Cumulative incidence ...